VTVT — vTv Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $70.90m
- $36.26m
- $1.02m
Annual income statement for vTv Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.41 | 4 | 2.02 | 0 | 1.02 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 18.3 | 25.7 | 24.6 | 30 | 25.2 |
| Operating Profit | -11.9 | -21.7 | -22.5 | -30 | -24.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12.8 | -17.6 | -24.9 | -26 | -22.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -12.8 | -17.7 | -25.1 | -26 | -22.7 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.5 | -13 | -19.2 | -20.3 | -18.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.5 | -13 | -19.2 | -20.3 | -18.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -7.21 | -7.87 | -10.2 | -7.55 | -3.2 |